Side-by-side · Research reference
DihexavsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Dihexa
Survodutide
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Survodutide
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Evidence basis
Pre-clinical / Rodent models
Phase 2 RCT (obesity) · Phase 3 ongoing
Clinical status
No Phase 1, 2, or 3 trials published
—
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
Dihexa
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Dihexa
Survodutide
Human safety data
None available — no human clinical trials
—
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Dihexa
Survodutide
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
—
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
—
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
—
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.